Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Clin Rheumatol ; 26(2): e49-e52, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32073534
2.
PLoS One ; 13(8): e0198881, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30157195

RESUMEN

OBJECTIVE: To identify in vitro inhibitors of xanthine crystallization that have potential for inhibiting the formation of xanthine crystals in urine and preventing the development of the renal calculi in patients with xanthinuria. METHODS: The formation of xanthine crystals in synthetic urine and the effects of 10 potential crystallization inhibitors were assessed using a kinetic turbidimetric system with a photometer. The maximum concentration tested for each compound was: 20 mg/L for 3-methylxanthine (3-MX); 40 mg/L for 7-methylxanthine (7-MX), 1-methylxanthine (1-MX), theobromine (TB), theophylline, paraxanthine, and caffeine; 45 mg/L for 1-methyluric acid; 80 mg/L for 1,3-dimethyluric acid; and 200 mg/L for hypoxanthine. Scanning electron microscopy was used to examine the morphology of the crystals formed when inhibitory effects were observed. RESULTS: Only 7-MX, 3-MX, and 1-MX significantly inhibited xanthine crystallization at the tested concentrations. Mixtures of inhibitors had an additive effect rather than a synergistic effect on crystallization. CONCLUSION: Two of the inhibitors identified here-7-MX and 3-MX-are major metabolites of TB. In particular, after TB consumption, 20% is excreted in the urine as TB, 21.5% as 3-MX, and 36% as 7-MX. Thus, consumption of theobromine could protect patients with xanthinuria from the development of renal xanthine calculi. Clinical trials are necessary to demonstrate these effects in vivo.


Asunto(s)
Precipitación Química/efectos de los fármacos , Cálculos Renales/química , Cálculos Renales/prevención & control , Urolitiasis , Xantina/química , Xantinas/farmacología , Aldehído Oxidasa/deficiencia , Aldehído Oxidasa/orina , Cristalización , Regulación hacia Abajo/efectos de los fármacos , Humanos , Técnicas In Vitro , Errores Innatos del Metabolismo/prevención & control , Errores Innatos del Metabolismo/orina , Errores Innatos del Metabolismo de la Purina-Pirimidina/prevención & control , Errores Innatos del Metabolismo de la Purina-Pirimidina/orina , Urolitiasis/prevención & control , Urolitiasis/orina , Xantina/antagonistas & inhibidores , Xantina/orina , Xantina Deshidrogenasa/deficiencia , Xantina Deshidrogenasa/orina
3.
Toxicol Appl Pharmacol ; 353: 102-108, 2018 08 15.
Artículo en Inglés | MEDLINE | ID: mdl-29935280

RESUMEN

BACKGROUND: The aim of our study was to identify the genetic background of thiopurine-induced toxicity in a patient with a wild-type thiopurine methyltransferase genotype and activity. A 38-year-old Caucasian woman presented with cutaneous necrotizing vasculitis pancytopenia one month after starting azathioprine therapy. METHODS: During a routine biochemical follow-up of the patient, undetectable serum uric acid (<10 µl) was observed. A high performance liquid chromatography analysis of urinary purines revealed increased levels of xanthine (137 mmol/mol creatinine). The suspected diagnosis of hereditary xanthinuria, a rare autosomal recessive disorder of the last two steps of purine metabolism, was confirmed by sequence analysis. RESULTS: An analysis of XDH/XO and AOX1 revealed common polymorphisms, while analysis of the MOCOS gene identified a rare homozygous variant c.362C > T. Dysfunction of this variant was confirmed by significantly decreased xanthine dehydrogenase/oxidase activity in the patient's plasma (<2% of control mean activity). CONCLUSIONS: We present a biochemical, enzymatic, and molecular genetic case study suggesting an important association between a hitherto undescribed dysfunction variant in the MOCOS gene and thiopurine-induced toxicity. The identified variant c.362C > T results in slower thiopurine metabolism caused by inhibition of 6-mercaptopurine oxidation (catabolism) to 6-thioxanthine and 6-thiouric acid, which increases the formation of the nucleotide 6-thioguanine, which is toxic. This is the first clinical case to identify the crucial role of the MOCOS gene in thiopurine intolerance and confirm the impact of genetic variability of purine enzymes on different therapeutic outcomes in patients undergoing thiopurine treatment.


Asunto(s)
Aldehído Oxidasa/deficiencia , Mercaptopurina/análogos & derivados , Errores Innatos del Metabolismo de la Purina-Pirimidina/genética , Sulfurtransferasas/genética , Xantina Deshidrogenasa/deficiencia , Adulto , Aldehído Oxidasa/genética , Femenino , Humanos , Mercaptopurina/efectos adversos , Mercaptopurina/metabolismo , Metiltransferasas/genética , Polimorfismo Genético/genética , Ácido Úrico/sangre , Xantina/orina , Xantina Deshidrogenasa/genética , Xantina Oxidasa/genética
4.
Artículo en Inglés | MEDLINE | ID: mdl-29723117

RESUMEN

Hereditary xanthinuria (type I) is caused by an inherited deficiency of the xanthine oxidorectase (XDH/XO), and is characterized by very low concentration of uric acid in blood and urine and high concentration of urinary xanthine, leading to urolithiasis. Type II results from a combined deficiency of XDH/XO and aldehyde oxidase. Patients present with hematuria, renal colic, urolithiasis or even acute renal failure. Clinical symptoms are the same for both types. In a third type, clinically distinct, sulfite oxidase activity is missing as well as XDH/XO and aldehyde oxidase. The prevalence is not known, but about 150 cases have been described so far. Hypouricemia is sometimes overlooked, that´s why we have set up the diagnostic flowchart. This consists of a) evaluation of uric acid concentrations in serum and urine with exclusion of primary renal hypouricemia, b) estimation of urinary xanthine, c) allopurinol loading test, which enables to distinguish type I and II; and finally assay of xanthine oxidoreductase activity in plasma with molecular genetic analysis. Following this diagnostic procedure we were able to find first patients with hereditary xanthinuria in our Czech population. We have detected nine cases, which is one of the largest group worldwide. Four patients were asymptomatic. All had profound hypouricemia, which was the first sign and led to referral to our department. Urinary concentrations of xanthine were in the range of 170-598 mmol/mol creatinine (normal < 30 mmol/mol creatinine). Hereditary xanthinuria is still unrecognized disorder and subjects with unexplained hypouricemia need detailed purine metabolic investigation.


Asunto(s)
Aldehído Oxidasa/deficiencia , Errores Innatos del Metabolismo/epidemiología , Errores Innatos del Metabolismo de la Purina-Pirimidina/epidemiología , Purinas/metabolismo , Xantina Deshidrogenasa/deficiencia , Xantina Deshidrogenasa/metabolismo , Adulto , Aldehído Oxidasa/sangre , Aldehído Oxidasa/orina , Alopurinol/metabolismo , Niño , Preescolar , República Checa/epidemiología , Diagnóstico Diferencial , Humanos , Errores Innatos del Metabolismo/sangre , Errores Innatos del Metabolismo/diagnóstico , Errores Innatos del Metabolismo/orina , Errores Innatos del Metabolismo de la Purina-Pirimidina/sangre , Errores Innatos del Metabolismo de la Purina-Pirimidina/diagnóstico , Errores Innatos del Metabolismo de la Purina-Pirimidina/orina , Defectos Congénitos del Transporte Tubular Renal/sangre , Defectos Congénitos del Transporte Tubular Renal/epidemiología , Defectos Congénitos del Transporte Tubular Renal/orina , Ácido Úrico/sangre , Ácido Úrico/orina , Cálculos Urinarios/sangre , Cálculos Urinarios/epidemiología , Cálculos Urinarios/orina , Xantina/sangre , Xantina/orina , Xantina Deshidrogenasa/sangre , Xantina Deshidrogenasa/orina
5.
Mol Genet Metab ; 117(1): 1-4, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26653176

RESUMEN

Molybdenum cofactor deficiency (MoCD) is a severe autosomal recessive inborn error of metabolism first described in 1978. It is characterized by a neonatal presentation of intractable seizures, feeding difficulties, severe developmental delay, microcephaly with brain atrophy and coarse facial features. MoCD results in deficiency of the molybdenum cofactor dependent enzymes sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase and mitochondrial amidoxime reducing component. The resultant accumulation of sulfite, taurine, S-sulfocysteine and thiosulfate contributes to the severe neurological impairment. Recently, initial evidence has demonstrated early treatment with cyclic PMP can turn MoCD type A from a previously neonatal lethal condition with only palliative options, to near normal neurological outcomes in affected patients. We review MoCD and focus on describing the currently published evidence of this exciting new therapeutic option for MoCD type A caused by pathogenic variants in MOCD1.


Asunto(s)
Errores Innatos del Metabolismo de los Metales , Aldehído Oxidasa/deficiencia , Cisteína/análogos & derivados , Cisteína/metabolismo , Humanos , Errores Innatos del Metabolismo de los Metales/metabolismo , Errores Innatos del Metabolismo de los Metales/terapia , Compuestos Organofosforados/uso terapéutico , Oximas/metabolismo , Pterinas/uso terapéutico , Sulfito-Oxidasa/deficiencia , Sulfitos/metabolismo , Tiosulfatos/metabolismo , Xantina Deshidrogenasa/deficiencia
6.
Cell Physiol Biochem ; 35(6): 2412-21, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25967871

RESUMEN

BACKGROUND: Hypouricemia is caused by various diseases and disorders, such as hepatic failure, Fanconi renotubular syndrome, nutritional deficiencies and genetic defects. Genetic defects of the molybdoflavoprotein enzymes induce hypouricemia and xanthinuria. Here, we identified a patient whose plasma and urine uric acid levels were both extremely low and aimed to identify the pathogenic gene and verify its mechanism. METHODS: Using next-generation sequencing (NGS), we detected a mutation in the human molybdenum cofactor sulfurase (MCSU) gene that may cause hypouricemia. We cultured L02 cells, knocked down MCSU with RNAi, and then detected the uric acid and MCSU concentrations, xanthine oxidase (XOD) and xanthine dehydrogenase (XDH) activity levels, and xanthine/hypoxanthine concentrations in cell lysates and culture supernatants. RESULTS: The NGS results showed that the patient had a mutation in the human MCSU gene. The in vitro study showed that RNAi of MCSU caused the uric acid, human MCSU concentrations, the XOD and XDH activity levels among cellular proteins and culture supernatants to be extremely low relative to those of the control. However, the xanthine/hypoxanthine concentrations were much higher than those of the control. CONCLUSIONS: We strongly confirmed the pathogenicity of the human MCSU gene.


Asunto(s)
Aldehído Oxidasa/deficiencia , Mutación/genética , Errores Innatos del Metabolismo de la Purina-Pirimidina/genética , Sulfurtransferasas/genética , Xantina Deshidrogenasa/deficiencia , Adulto , Aldehído Oxidasa/genética , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Humanos , Masculino , Ácido Úrico/metabolismo , Xantina , Xantina Deshidrogenasa/genética , Xantina Deshidrogenasa/metabolismo , Xantina Oxidasa/metabolismo
7.
Toxicol Sci ; 133(1): 22-8, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23462233

RESUMEN

Aldehyde oxidase (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (CYPs) and other detoxification systems. Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions. The goal of this study was to establish the relative importance of AOX and CYPs in vivo using the mouse model. The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain. None of these approaches reduced CYP activity measured in vitro with an isozyme nonspecific substrate. Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls. When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice. The other IMI nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with tungsten, hydralazine, and in the AOX-deficient mice, respectively. Thus, decreasing liver AOX activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of IMI-treated mice. Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains. This is the first study to establish the in vivo relevance of AOX in neonicotinoid metabolism in mammals and one of the first for xenobiotics in general.


Asunto(s)
Aldehído Oxidasa/metabolismo , Imidazoles/metabolismo , Insecticidas/metabolismo , Nitrocompuestos/metabolismo , Xenobióticos/metabolismo , Aldehído Oxidasa/deficiencia , Aldehído Oxidasa/genética , Animales , Biotransformación , Citosol/efectos de los fármacos , Citosol/enzimología , Drosophila melanogaster/efectos de los fármacos , Drosophila melanogaster/enzimología , Drosophila melanogaster/genética , Imidazoles/química , Imidazoles/farmacocinética , Insecticidas/química , Insecticidas/farmacocinética , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Ratones , Ratones Endogámicos DBA , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Estructura Molecular , Neonicotinoides , Nitrocompuestos/química , Nitrocompuestos/farmacocinética , Oxidación-Reducción , Especificidad de la Especie , Xenobióticos/química , Xenobióticos/farmacocinética
8.
Int J Mol Sci ; 13(11): 15475-95, 2012 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-23203137

RESUMEN

Xanthine oxidoreductase (XOR) catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid with concomitant reduction of either NAD+ or O(2). The enzyme is a target of drugs to treat hyperuricemia, gout and reactive oxygen-related diseases. Human diseases associated with genetically determined dysfunction of XOR are termed xanthinuria, because of the excretion of xanthine in urine. Xanthinuria is classified into two subtypes, type I and type II. Type I xanthinuria involves XOR deficiency due to genetic defect of XOR, whereas type II xanthinuria involves dual deficiency of XOR and aldehyde oxidase (AO, a molybdoflavo enzyme similar to XOR) due to genetic defect in the molybdenum cofactor sulfurase. Molybdenum cofactor deficiency is associated with triple deficiency of XOR, AO and sulfite oxidase, due to defective synthesis of molybdopterin, which is a precursor of molybdenum cofactor for all three enzymes. The present review focuses on mutation or chemical modification studies of mammalian XOR, as well as on XOR mutations identified in humans, aimed at understanding the reaction mechanism of XOR and the relevance of mutated XORs as models to estimate the possible side effects of clinical application of XOR inhibitors.


Asunto(s)
Errores Innatos del Metabolismo/genética , Errores Innatos del Metabolismo/metabolismo , Mutación , Xantina Deshidrogenasa/deficiencia , Xantina Deshidrogenasa/genética , Xantina Deshidrogenasa/metabolismo , Aldehído Oxidasa/deficiencia , Aldehído Oxidasa/genética , Aldehído Oxidasa/metabolismo , Animales , Diagnóstico Diferencial , Activación Enzimática , Estudios de Asociación Genética , Humanos , Errores Innatos del Metabolismo/diagnóstico , Conformación Proteica , Dominios y Motivos de Interacción de Proteínas , Errores Innatos del Metabolismo de la Purina-Pirimidina/diagnóstico , Errores Innatos del Metabolismo de la Purina-Pirimidina/genética , Errores Innatos del Metabolismo de la Purina-Pirimidina/metabolismo , Xantina/metabolismo , Xantina Deshidrogenasa/química
9.
Mol Genet Metab ; 91(1): 23-9, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17368066

RESUMEN

Classical xanthinuria type II is an autosomal recessive disorder characterized by deficiency of xanthine dehydrogenase and aldehyde oxidase activities due to lack of a common sulfido-olybdenum cofactor (MoCo). Two mutations, both in the N-terminal domain of the Human Molybdenum Cofactor Sulfurase (HMCS), were reported in patients with type II xanthinuria. Whereas the N-terminal domain of HMCS was demonstrated to have cysteine desulfurase activity, the C-terminal domain hypothetically transfers the sulfur to the MoCo. We describe the first mutation in the C-terminal domain of HMCS identified in a Bedouin-Arab child presenting with urolithiasis and in an asymptomatic Jewish female. Patients were diagnosed with type II xanthinuria by homozygosity mapping and/or allopurinol loading test. The Bedouin-Arab child was homozygous for a c.2326C>T (p.Arg776Cys) mutation, while the female patient was compound heterozygous for this and a novel c.1034insA (p.Gln347fsStop379) mutation in the N-terminal domain of HMCS. Cosegregation of the homozygous mutant genotype with hypouricemia and hypouricosuria was demonstrated in the Bedouin family. Haplotype analysis indicated that p.Arg776Cys is a recurrent mutation. Arg776 together with six surrounding amino acid residues were found fully conserved and predicted to be buried in homologous eukaryotic MoCo sulfurases. Moreover, Arg776 is conserved in a diversity of eukaryotic and prokaryotic proteins that posses a domain homologous to the C-terminal domain of HMCS. Our findings suggest that Arg776 is essential for a core structure of the C-terminal domain of the HMCS and identification of a mutation at this site may contribute clarifying the mechanism of MoCo sulfuration.


Asunto(s)
Aldehído Oxidasa/deficiencia , Sustitución de Aminoácidos , Sulfurtransferasas/genética , Xantina Deshidrogenasa/deficiencia , Xantinas/orina , Aldehído Oxidasa/genética , Aldehído Oxidasa/metabolismo , Alopurinol/metabolismo , Secuencia de Aminoácidos , Arginina/genética , Secuencia de Bases , Coenzimas/metabolismo , Cisteína/genética , Femenino , Homocigoto , Humanos , Recién Nacido , Masculino , Metaloproteínas/metabolismo , Cofactores de Molibdeno , Mutación , Linaje , Filogenia , Estructura Terciaria de Proteína , Pteridinas/metabolismo , Alineación de Secuencia , Sulfurtransferasas/química , Sulfurtransferasas/metabolismo , Xantina Deshidrogenasa/genética , Xantina Deshidrogenasa/metabolismo , Xantinas/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA